NIOPAM

Uses

Neuroradiology: Lumber myelography, thoraco-cervical myelography

Angiography: Cerebral angiography, selective coronary angiography, left ventriculography, aortography, angiocadiography, selective visceral arteriography, peripheral arteriography, digital subtraction angiography, venography, urography

Other diagnostic procedures: Contrast enhancement in CT scanning, arthrography, fistulography.

Dosage

NIOPAM dosage

Adult dosage:

• Neurology:Lumber myelography: NIOPAM 370, 6-13 ml,
• Thoraco-cervical myelography: NIOPAM 370, 6-13 ml.
• Urography: NIOPAM 370, 40-80 ml IV up to 1.5 ml/kg in severe renal disease.

Children:

• Usual Dose: 1-2.5 ml/kg
• Other Diagnostic Procedure: Contrast enhancement in CT scanning: NIOPAM 370, 0.5-2.0 ml/kg

Angiography: Cerebral angiography: NIOPAM 370, 6-13 ml

Selective coronary arteriography: NIOPAM 370, 4-8 ml/artery

Peripheral arteriography: NIOPAM 370, 20-50 ml

Venography: NIOPAM 370, 24-60 ml

Angiocardiography: NIOPAM 370, 30-80 ml

Left ventriculography: NIOPAM 370, 30-80 ml

Percutaneous transfemoral or renal arteriography: NIOPAM 370, 30 ml

Selective renal arteriography: NIOPAM370, 5-10 ml

Hepatic angiography: NIOPAM 370, 70 ml

Coeliac angiography: NIOPAM 370, 40-70 ml

Superior mesenteric angiography: NIOPAM 370, 25-50 ml

Inferior mesenteric angiography: NIOPAM 370, 5-30 ml

Digital subtraction angiography: 30-50 ml (10-20 ml/sec) of NIOPAM 370, IV 25 ml (left ventricle), 2-5 ml (coronary arteries) ,15 ml/sec. of NIOPAM 370 i.a for cardiac imaging

NEURORADIOLOGY-Lumber myelography: A slow sub-arachnoid injection is made through a fine lumber puncture needle into one of the lower interspinous spaces (L3-L4 or L4-L5). Optimum contrast appears immediately after injections and films should be obtained promptly.

Thoraco-cervical myelography: Following a slow sub-arachnoid injection the patient should be turned on his/her side and tilted 10o-20o head down under fluoroscopic control. In this manner it is possible to control movement of the contrast medium column into the dorsal region.If the cervical region is to be examined, the contrast medium should be run into the cervical region first, before the examination of the dorsal areas where it is progressively diluted. NIOPAM 300/370 may also be injected sub-occipitally or by lateral puncture technique .Care should be taken to ensure that the contrast medium does not move intracranially. It is generally recommended that in intrathecal use the patient should remain with a raised bed head and be kept well hydrated; following hydration it is preferable that the patient be allowed to be ambulatory .

ANGIOGRAPHY-Cerebral angiography: Any current technique is suitable for radiological visualization of the cerebral vasculature with NIOPAM 370/300 injection. Carotid and vertebral angiography, performed by catheterization or percutaneous injection techniques, require rapid injection which, if necessary, may be repeated.

Peripheral arteriography and venography: Percutaneous injection into the appropriate blood vessel is used for visualization of peripheral arteries and veins.

Angiocardiography, left ventriculography, selective coronary arteriography: NIOPAM 370/300 injection may be administered by rapid injection through a catheter into a suitable peripheral artery or vein. It can also be introduced under pressure through a cardiac catheter in to any of the heart chambers, or injected into large vessel for immediate visualization. The contrast medium may also be administered during selective catheterization of the coronary arteries.

Aortography: The contrast medium may be introduced directly or by intra-arterial injection for visualization of the aorta and its main branches.Selective visceral angiography: Visualization can be achieved by selective catheterization and injection into the hepatic, coeliac or mesenteric arteries.

Digital subtraction angiography: For cardiac imaging the contrast medium may be administered intra-arterially by selective catheterization to provide substrated images. NIOPAM 370/300 injected intravenously either centrally or peripherally is also recommended for use this modality.

UROGRAPHY-The contrast medium injected intravenously and rapidly eliminated through the kidneys. In patients with severe renal failure, high dose urography should be used.

OTHER DIAGNOSTIC PROCEDURES-Arthrography: Visualization of joint cavities and articular surfaces can be achieved either single or double contrast examination.

Contrast enhancement in CT scanning: Contrast enhancement for brain scans can be achieved between one and three minutes after i.v. injection. NIOPAM 370/300 are also be used for total body scanning examinations after i.v.administration as a bolus, as a drip infusion or by combination of the two methods.

Side Effects

Common side effects are arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria.

Precaution

May inhibit blood coagulation. Multiple myeloma or other paraproteinaemia. Sickle-cell disease. Known or suspected phaeochromocytoma (monitor closely). Hyperthyroidism. Ensure adequate hydration. History of a previous sensitivity to a contrast medium, sensitivity to iodine, bronchial asthma, hay fever and food allergy. Monitor patients with CHF. Avoid angiography in patients with homocystinuria. Severe arterial or venous disease. Severe renal impairment, combined renal and hepatic disease or anuria, especially when large doses are used. Pregnancy and lactation.

Interaction

NIOPAM may interfere with thyroid function. Biguanide compete for excretion in the kidneys with contrast media and this could lead to reduction in kidney function. Patient taking Metformin or other Biguanides should therefore not take any doses of Metformin for 48 hours before or 48 hours after the X-ray examination.

Food Interaction

NIOPAM Hypertension interaction

[Moderate] In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.

Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.

NIOPAM Drug Interaction

Major: haloperidol, haloperidolUnknown: aspirin, aspirin, epinephrine, epinephrine, amoxicillin, amoxicillin, multivitamin, multivitamin, ginkgo, ginkgo, ipratropium, ipratropium, acetaminophen, acetaminophen, procaine penicillin, procaine penicillin, valproic acid, valproic acid

NIOPAM Disease Interaction

Major: hyperthyroidism, pheochromocytomaModerate: sickle cell disease, multiple myeloma, myasthenia gravis, asthma/allergies, renal disease, allergic reactions, congestive heart failure, dehydration

Pregnancy & Breastfeeding use

NIOPAM injection should be administered in pregnancy only if the procedure is considered essential by the physician.

Contraindication

There are no definite or absolute contraindications to the use of Amidol, with the possible exception of waldenstrom's macroglobulinemia, multiple myeloma and severe liver and kidney disease.

Acute Overdose

Treatments of an overdose is directed toward the support of all vital functions and prompt institution of symptomatic therapy.

Storage Condition

Store at 20-25° C

Innovators Monograph

You find simplified version here NIOPAM